Table 3.

Classifiers of tumor response to sorafenib

Rank	Gene combination	Combination	Sensitivity, %	Specificity, %	AUC	Accuracy	PPV	NPV
1	mTOR_VEGFR2_c-KlT_c-RAF	4	77.78	81.99	0.779	81.82	15.56	98.86
2	mTOR_c-KlT_c-RAF	3	77.78	81.52	0.778	81.36	15.22	98.85
3	mTOR_VEGFR2_c-KlT_c-RAF_FGFR1	5	77.78	81.52	0.770	81.36	15.22	98.85
4	VEGFR2_c-KlT_c-RAF	3	77.78	80.57	0.781	80.45	14.58	98.84
5	mTOR_c-KlT_c-RAF_FGFR1	4	77.78	80.09	0.764	80.00	14.29	98.83
6	c-KlT_c-RAF	2	77.78	77.73	0.791	77.73	12.96	98.80
7	c-KlT_c-RAF_FGFR1	3	77.78	77.73	0.769	77.73	12.96	98.80
8	VEGFR2_c-KlT_c-RAF_FGFR1	4	77.78	77.25	0.765	77.27	12.73	98.79
9	mTOR_VEGFR2_c-KlT_c-RAF_EGFR	5	77.78	73.46	0.769	73.46	11.11	98.73
	mTOR	1	44.44	87.68	0.600	85.91	13.33	97.37
	VEGFR2	1	88.89	36.02	0.618	38.18	5.59	98.70
	c-KlT	1	88.89	56.87	0.731	58.18	8.08	99.17
	c-RAF	1	55.56	86.73	0.706	85.45	15.15	97.86
	mTOR_VEGFR2_PDGFRB_c-KlT_EGFR_FGFR1	6	55.56	82.94	0.730	81.82	12.20	97.77
	mTOR_VEGFR2_PDGFRB_c-KlT_c-KlT_EGFR_FGFR1	7	88.89	58.29	0.747	59.55	8.33	99.19

AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; mTOR, mammalian target of rapamycin; VEGFR2, vascular endothelial growth factor receptor 2; c-KIT, KIT proto-oncogene receptor tyrosine kinase; c-RAF, Raf-1 proto-oncogene serine/threonine kinase; FGFR1, fibroblast growth factor receptor 1; EGFR, epidermal growth factor receptor; PDGFRB, platelet-derived growth factor receptor beta.